|
|
Article: Sleep Maintenance Data Less Convincing Vanda Improves Sleep Onset in Phase III Insomnia Trial.
- Article from:
- BIOWORLD Today
- Article date:
- June 27, 2008
- Author:
CopyrightCOPYRIGHT 2008 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Byline: Trista Morrison, Staff Writer
Shares of Vanda Pharmaceuticals Inc. rose and then fell on Thursday as investors tried to digest top-line data from the company's Phase III trial of tasimelteon (VEC-162) in chronic insomnia.
In the study, 322 patients were randomized to receive 20 mg of tasimelteon, 50 mg of tasimelteon or placebo for four weeks. Both doses of the drug hit the primary endpoint by significantly improving short-term sleep onset, according to latency to persistent sleep (LPS) data measured by polysomnography on the first and eighth nights.
Specifically, while patients in the trial normally spent more than two hours trying to ...